Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis International (Details)

v3.21.1
Licensing and Other Arrangements - Novartis International (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 21, 2020
USD ($)
Sep. 30, 2015
item
Sep. 30, 2015
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers       $ 19 $ 500      
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation $ 7,300              
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period   180 days            
Number of performance obligations | item   1            
Cash payment received 17,700             $ 37,000
Revenue from contracts with customers 25,000     0   $ 0 $ 10,000 $ 37,000
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 445,000   $ 480,000          
Royalty payment period   10 years            
Contract assets       0   0    
Contract liabilities       0   0    
Capitalized contract costs       $ 0   $ 0